A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Comparator: Sitagliptin phosphate
Comparator: Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- 18 - 78 years of age
- Currently on metformin monotherapy
Exclusion Criteria:
- History of Type 1 diabetes mellitus or ketoacidosis
- Currently on a weight loss program and not in the maintenance phase or has started on a weight loss medication within the last 8 weeks
- Has undergone surgery requiring general anesthesia within the past 4 weeks or has planned major surgery
- Currently participating in a study or has participated in a study with or without an investigational compound or device within the past 12 weeks
- History of active liver disease such as chronic active hepatitis B or C, cirrhosis or symptomatic gallbladder disease
- HIV positive
- Pregnant, breast-feeding or planning to become pregnant during the study
- User of recreational or illicit drugs or has a recent history (within the past year) of drug or alcohol abuse or dependence
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Sitagliptin
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change From Baseline in Hemoglobin A1c (A1C) at Week 24
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Secondary Outcome Measures
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Full Information
NCT ID
NCT00813995
First Posted
December 19, 2008
Last Updated
April 7, 2017
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00813995
Brief Title
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
Official Title
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
December 9, 2008 (Actual)
Primary Completion Date
August 9, 2010 (Actual)
Study Completion Date
August 9, 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
395 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sitagliptin
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Comparator: Sitagliptin phosphate
Other Intervention Name(s)
GLUCOPHAGE®
Intervention Description
All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
Intervention Type
Drug
Intervention Name(s)
Comparator: Placebo
Other Intervention Name(s)
GLUCOPHAGE®
Intervention Description
All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
Primary Outcome Measure Information:
Title
Change From Baseline in Hemoglobin A1c (A1C) at Week 24
Description
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Time Frame
Baseline and Week 24
Secondary Outcome Measure Information:
Title
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day
Description
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Time Frame
Baseline and Week 24
Title
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day
Description
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Time Frame
Baseline and Week 24
Title
Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
Description
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Time Frame
Baseline and Week 24
Title
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Description
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Time Frame
Baseline and Week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 - 78 years of age
Currently on metformin monotherapy
Exclusion Criteria:
History of Type 1 diabetes mellitus or ketoacidosis
Currently on a weight loss program and not in the maintenance phase or has started on a weight loss medication within the last 8 weeks
Has undergone surgery requiring general anesthesia within the past 4 weeks or has planned major surgery
Currently participating in a study or has participated in a study with or without an investigational compound or device within the past 12 weeks
History of active liver disease such as chronic active hepatitis B or C, cirrhosis or symptomatic gallbladder disease
HIV positive
Pregnant, breast-feeding or planning to become pregnant during the study
User of recreational or illicit drugs or has a recent history (within the past year) of drug or alcohol abuse or dependence
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Citations:
PubMed Identifier
22672586
Citation
Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012 Sep;4(3):227-37. doi: 10.1111/j.1753-0407.2012.00213.x.
Results Reference
derived
Learn more about this trial
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
We'll reach out to this number within 24 hrs